12:00 AM
Apr 17, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Mobic meloxicam non-steroidal anti-inflammatory drug regulatory update

The FDA granted marketing approval for Boehringer's Mobic once daily cyclooxygenase (COX) inhibitor to treat osteoarthritis. The company said that...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >